Search

Introduction: International guidelines recommend that external cephalic version (ECV) be offered to all women with single fetuses in breech presentation at term. In Norway, ECV is not offered routinely; the national clinical guidelines advice that birth units capable of offering ECV for breech pregnancies make their own practice decisions. This study was performed to determine the extent to which Norwegian birth units offer ECV to pregnant women with fetuses in breech presentations at term, and to identify factors that might influence the use of ECV., Material and Methods: A survey of all 39 obstetric birth units providing ECV in Norway was conducted using a self-reporting questionnaire about ECV availability, attitudes, clinical procedures, perceived competence, and outcome expectations., Results: Chief obstetricians from all birth units responded. Twenty-six (67%) respondents reported that their units offered ECV for breech presentation at term to a large degree. Thirty-one (80%) respondents reported a large degree of competence in performing ECV. Thirty-three (85%) units followed local ECV procedures. Nineteen (49%) units provided standardized information about the procedure to pregnant women. The respondents had different views about who should be offered ECV, and varying knowledge about ECV outcomes., Conclusions: The majority of Norwegian birth units offer ECV to pregnant women with fetuses in breech position to a large extent. However, the survey results reveal challenges related to ECV information provision to pregnant women, determination of women's eligibility for ECV attempts, and familiarity and agreement with the knowledge base regarding ECV., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.)

Effects on serum lipids were examined in a double blind placebo controlled trial including 111 male and females with cholesterol values higher than 7.0 mmol/l. The patients were treated with 6 g Almarin capsules consisting of the highly concentrated fish-oil EPAX 6000 EE in a daily dose corresponding to 2.1 g eicosapentaenoic acid and 1.5 g docosahexaenoic acid, or olive oil control for 12 weeks. We registered the effects on serum triglycerides, total cholesterol and HDL cholesterol. Compared with baseline values a 19.5% median reduction in serum triglycerides could be observed in the n-3 treated group. This reduction was significantly different from control and baseline values. We also observed a favourable trend towards lower total serum cholesterol and higher serum HDL cholesterol.